MabPlex International, a Chinese contract developer and manufacturer of biopharmaceuticals, has garnered over 500 million yuan ($71 million) in a Series B round of financing led by private equity firms DT Capital Partners and Huajin Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
